22
May
2008
CLSDF: Gone Fishin’, Back June 2nd
Posted in My Rants
That’s right we here at CLSDF are closing up shop for the week, it is time for a little R&R, but not too much. We have an ambitious schedule planned starting with an Egyptian excursion to the Pyramids, the Great Wall, Shanghai and Beijing, the Taj Mahal, Dehli and the Sariska tiger reserve, Machu Picchu, [...]
22
May
2008
Miragen Therapeutics, a biopharmaceutical company focused on the discovery and development of therapies for cardiovascular and muscle disease based on microRNA biology has closed an $8M Series A financing co-led by Atlas Venture and Boulder Ventures. The Miragen scientific co-founders include successful academician serial entrepreneurs Eric Olson, Ph.D., Michael Bristow, M.D., Ph.D., and Marvin Caruthers, [...]
21
May
2008
Array BioPharma (NASDAQ: ARRY) and AstraZeneca (NYSE: AZN) recently announced plans for two additional randomized Phase II trials for ARRY-886, an oncology small molecule inhibitor targeting the Ras/Raf/MEK/ERK signaling pathway. The trials, scheduled to initiate in 2H08, will test ARRY-886 in combination with chemotherapeutic agents in melanoma and non small cell lung cancer patients.
Recall [...]
21
May
2008
Congratulations to Jerome Rifkin and Tensegrity Prosthetics for their wonderful feature in the June edition of Popular Science! Read the article (here) then be certain to watch the video (here).
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!*NOTE* Read the new eBook CLSDF [...]
20
May
2008
On the heels of Allos Therapeutics (NASDAQ: ALTH) reporting of positive interim data for their pivotal Phase II PDX (pralatrexate) trial, where a 29% of 65 T-cell lymphoma patients had either a complete or partial response, have now unveiled their follow-on financing strategy for ongoing clinical requirements in addition to preclinical R&D of pipeline candidates, [...]
19
May
2008
Replidyne (NASDAQ: RDYN) has been served with a Demand for Arbitration from MEDA Manufacturing alleging that the Company breached its obligations under a 2005 supply agreement. In April 2007, Replidyne provided notice to MEDA of its termination of the Supply Agreement in accordance with certain termination provisions, and believes that it did not have any [...]
16
May
2008
Some people read the Old Testament, others may read the New Testament, the Koran, the Bhagavad Gita, or the Guru Granth Sahib, my bible has become…Valuation in Life Sciences: A Practical Guide by Dr. Boris Bogdan and Ralph Villiger. This work has emerged as my one unambiguous go-to text when it comes to evaluation and [...]
14
May
2008
It is not the first, will not be the last, name change that is. Alphasniffer (Boulder) has announced a new corporate identity, introducing…BiOptix. This modification in moniker echoes how the Colorado life science ecosystem is certainly maturing from a research and discovery engine to the logical progression of more of a commercialization focus, this second [...]
13
May
2008
Did you know that Agilent Technologies (NYSE: A) provides bio-analytical and electronic solutions to a variety of industries; the company’s bio-analytical measurement business segment provides application-focused solutions that include instruments, software, consumables, and services that enable their customers to identify, quantify, and analyze physical and biological properties. Its product categories include gas chromatography, liquid chromatography, [...]
09
May
2008
Yesterday Replidyne (NASDAQ: RDYN) held their annual shareholder meeting and 1Q08 conference call. With an anticipated burn rate of approximately $10M per quarter Replidyne’s current cash position just north of $78M positions operations to continue well into 2009. Considering the new strategic initiatives including restructuring, cash conservation and the difficult decision to terminate enrollment [...]
09
May
2008
BioBootCamp Day 1: Getting In Shape
Posted in My Rants
It was buzz cuts and pushups, nuts and bolts, project management and IP protection, reimbursement and regulatory, & compliance and management teams all crammed into Day 1 of BioBootCamp, whoa, I am exhausted and we are only half-way through. Yes sir! Not only has the content been fantastic and the presenters polished, motivated and interactive [...]
08
May
2008
In a recent interview with the Star-Ledger, New Jersey-based Celgene (NASDAQ: CELG) Chief Executive Officer Sol J. Barer, Ph.D. provided some insight as to the integration plans for Pharmion products and intellectual capital. Following is a portion of that Q&A.
Q: Celgene already was expanding its presence abroad. What does adding Pharmion do for you internationally?
A: [...]
07
May
2008
GW Carver Award to Gevo CEO
Posted in CO Private: Gevo
Perhaps not on many peoples radars…yet…Gevo (Denver) a next generation bio fuels company recently moved to town from Pasadena and Cal Tech, from where their intellectual property originates. Backed by Khosla Ventures and Sir Richard Branon’s Virgin Green Fund Gevo incorporates three novel technological elements enabling the scalable production of biofuels.
Recently during the World Congress [...]
Life Science Deal Flow PARTNERS
-
